press release

Nov. 11, 2021, 8:30 a.m. EST

Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand

FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, Nov. 11, 2021 /PRNewswire/ -- New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force (USPSTF) and from the US Food and Drug Administration are ensuring benefits realized by all—all by moving up the starting screening age of adults from 50 down to 45. In turn, market researchers are forecasting a CAGR growth of 8.5% and an overall expansion of the market by 2.2x through 2031 in the global colorectal cancer diagnostics market. According to Pew, more FDA approved in vitro diagnostic (IVD) tests and lab-developed tests (LDTs) are increasingly needed. Just in time for this surging new demand of diagnostic options, there has been plenty of innovation in the field of colorectal cancer screening, from developers such as Mainz BioMed B.V. /zigman2/quotes/230703458/composite MYNZ +26.95% , Exact Sciences Corporation /zigman2/quotes/206653925/composite EXAS +4.02% , Guardant Health /zigman2/quotes/201348336/composite GH -1.55% , Illumina /zigman2/quotes/203509482/composite ILMN +1.41% , Pacific Biosciences of California 'PacBio' /zigman2/quotes/203185043/composite PACB -5.83% .

Newly IPO'd Mainz BioMed B.V. /zigman2/quotes/230703458/composite MYNZ +26.95% is priming itself for a jump from Europe into the US market, with its flagship product ColoAlert—which is a non-invasive colorectal screening test that can be taken at home, with a rapid response and 92% specificity.

ColoAlert is already approved for commercial sale in the EU, and is currently developed out of its home country of Germany. The test is categorized as a non-invasive molecular genetic colorectal early detection stool test in combination with the fecal immunochemistry test (FIT) that's simple, fast, and accurate.

Mainz claims on its website that ColoAlert can deliver up to 60% fewer missed cases when compared to fecal immunochemical tests (FIT). According to internal data on the product, 98% of the patients who responded to an internal survey expressed satisfaction with the easy-to-use product.

In many ways, Mainz's ColoAlert product is expected to challenge its leading competitor, ColoGuard, manufactured and sold by Exact Sciences Corporation /zigman2/quotes/206653925/composite EXAS +4.02% .

There are many differences, however, including price points, and distribution, as ColoAlert is expected to use a decentralization business strategy by selling directly to a wide range of regional and national laboratory service providers, whereas all ColoGuard tests are currently analyzed through Exact Sciences' central laboratory.

ColoAlert has already received CE accreditation and is approved for sale in Europe, meaning Mainz BioMed will already have its established relationships with international distributors making for a smooth transition into other markets, should more approvals come down the line.

Mainz BioMed has stated that its FDA clinical study process for ColoAlert is set to be launched in H1 2022.

For Q3 2021, Exact Sciences Corporation /zigman2/quotes/206653925/composite EXAS +4.02% recently released its financial results, showing that the company generated revenue of $456.4 million—up 11.75% over the same period in 2020. Screening revenue alone for the company was $280.4 million, representing an increase of 31% year over year.

" Exact Sciences is entering an exciting period for its pipeline, generating evidence to support innovative tests that will help defeat cancer through earlier detection," said Kevin Conroy, chairman and CEO of Exact Sciences . "Our powerful commercial engine will help us achieve our mission by getting more people tested with Cologuard [®] , Oncotype DX [®] , and our future tests."

Recently genetic-screening company Illumina's /zigman2/quotes/203509482/composite ILMN +1.41% CEO Francis deSouza gave an interview with the Wall Street Journal about his company's breakthrough subsidiary start-up Grail, as a cancer diagnosing blood test.

"We know that cancer kills about 10 million people a year—about 600,000 in the U.S. And we know that even for some of the deadliest cancers, your odds of survival are much higher if you catch the cancer in stage 1 or stage 2," said Illumina CEO Francis deSouza. "So a blood test that can catch cancer early can truly be life-changing."

Grail doesn't pick up every cancer, but it can detect the 12 deadliest cancers with 60% accuracy, and has a false-positive rate of less than 1%.

"Today, there is nobody who is even starting the studies to develop a 50-cancer test like Grail, and once you start the study, it's still a few years before you actually get the test," adds deSouza. "We think there will also be blood tests for single cancers, for colorectal cancer and other cancers. Those won't compete with Grail. They will be complementary to Grail."

Data presented at the American College of Gastroenterology's Annual Scientific Meeting showed that the LUNAR-2 blooed test from Guardant Health /zigman2/quotes/201348336/composite GH -1.55% offered optimized sensitivity and specificity in identifying average-risk patients with early-stage CRC. The LUNAR-2 blood test aims to detect early-stage cancer in screen-eligible asymptomatic adults from a simple blood draw. 

"CRC screening saves lives, but we know that only about two-thirds of individuals get screened for CRC because current options, like a colonoscopy, are invasive and the preparation can be challenging, and other modalities, like stool based testing, have their own challenges to screening adherence," said AmirAli Talasaz, Guardant Health Co-CEO. "The study results show that the LUNAR-2 test could provide both patients and physicians with an easy-to-use and highly accurate CRC screening alternative in the form of a blood test."

Pacific Biosciences of California 'PacBio' /zigman2/quotes/203185043/composite PACB -5.83% is set to provide its Sequl IIe sequencing platforms to leading global genomics and diagnostic testing company, Prenetics Groups Limited —as the first is adding more comprehensive genetic screening services in Hong Kong, Southeast Asia and the UK.

Prenetics is using PacBio technology to apply epigenomics to both end-consumer oriented products, including medically-oriented products such as colorectal cancer and liver cancer.

"The pairing of PacBio and Prenetics doesn't just offer opportunities in consumer genetic testing, but shows how Sequel IIe can be used to make advances in biomedical research, clinical diagnostics and pharmaceutical solutions," said  Jonas Korlach, Chief Scientific Officer at PacBio . "We're very excited to see how our HiFi technology is being used by scientists all around the world to advance science."

To get more information Mainz BioMed /zigman2/quotes/230703458/composite MYNZ +26.95% , please visit here .

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
 
The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated forty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Mainz BioMed B.V.


FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
 
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
 
Media Contact:
FN Media Group, LLC
info@financialnews.com
+1(561)325-8757

Cision
View original content: https://www.prnewswire.com/news-releases/earlier-screening-and-aging-population-driving-surging-growth-in-colorectal-diagnostics-demand-301421922.html

SOURCE Microsmallcap.com

COMTEX_396730660/2454/2021-11-11T08:30:24

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

/zigman2/quotes/230703458/composite
US : U.S.: Nasdaq
$ 20.87
+4.43 +26.95%
Volume: 592,144
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
N/A
Rev. per Employee
N/A
loading...
/zigman2/quotes/206653925/composite
US : U.S.: Nasdaq
$ 78.43
+3.03 +4.02%
Volume: 2.24M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$13.62 billion
Rev. per Employee
$351,923
loading...
/zigman2/quotes/201348336/composite
US : U.S.: Nasdaq
$ 77.58
-1.22 -1.55%
Volume: 2.01M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$7.89 billion
Rev. per Employee
$397,987
loading...
/zigman2/quotes/203509482/composite
US : U.S.: Nasdaq
$ 405.14
+5.63 +1.41%
Volume: 1.03M
Jan. 14, 2022 4:00p
P/E Ratio
66.65
Dividend Yield
N/A
Market Cap
$63.32 billion
Rev. per Employee
$548,718
loading...
/zigman2/quotes/203185043/composite
US : U.S.: Nasdaq
$ 12.43
-0.77 -5.83%
Volume: 7.54M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.74 billion
Rev. per Employee
$295,218
loading...
/zigman2/quotes/230703458/composite
US : U.S.: Nasdaq
$ 20.87
+4.43 +26.95%
Volume: 592,144
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
N/A
Rev. per Employee
N/A
loading...
/zigman2/quotes/206653925/composite
US : U.S.: Nasdaq
$ 78.43
+3.03 +4.02%
Volume: 2.24M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$13.62 billion
Rev. per Employee
$351,923
loading...
/zigman2/quotes/206653925/composite
US : U.S.: Nasdaq
$ 78.43
+3.03 +4.02%
Volume: 2.24M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$13.62 billion
Rev. per Employee
$351,923
loading...
/zigman2/quotes/203509482/composite
US : U.S.: Nasdaq
$ 405.14
+5.63 +1.41%
Volume: 1.03M
Jan. 14, 2022 4:00p
P/E Ratio
66.65
Dividend Yield
N/A
Market Cap
$63.32 billion
Rev. per Employee
$548,718
loading...
/zigman2/quotes/201348336/composite
US : U.S.: Nasdaq
$ 77.58
-1.22 -1.55%
Volume: 2.01M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$7.89 billion
Rev. per Employee
$397,987
loading...
/zigman2/quotes/203185043/composite
US : U.S.: Nasdaq
$ 12.43
-0.77 -5.83%
Volume: 7.54M
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.74 billion
Rev. per Employee
$295,218
loading...
/zigman2/quotes/230703458/composite
US : U.S.: Nasdaq
$ 20.87
+4.43 +26.95%
Volume: 592,144
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
N/A
Rev. per Employee
N/A
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.